licensing– tag –

Strategic Review: Expanding from Monoclonal Antibodies into Diagnostics, RNA, and Cell Therapy Roche has long been a global leader in monoclonal antibody-based cancer therapies. Roche has long been a global leader in monoclonal antibody-...

Strategic Review: Immunology, Oncology, and Rare Diseases at the Core of J&J’s R&D-Driven Vision Johnson & Johnson (J&J) has strategically expanded into immunology, oncology, and rare diseases by acquiring biotech compani...

Strategic Review: Beyond Keytruda—Pivot to Next-Gen Modalities Merck (MSD in the U.S.) built a strong oncology franchise with Keytruda. As patents expire, Merck is investing in ADCs, RNA therapies, cell therapy, and precision immunology ...

Strategic Review: From mRNA Success to Diversification in Rare Diseases, ADCs, and RNA Editing Pfizer strengthened its biopharmaceutical base with the acquisition of Hospira and GSK’s vaccine assets in 2015, followed by a major expansion...